Open company graph database — free web & API
Login

Veritas In Silico Inc.

株式会社Veritas In Silico
Ticker
Listed market
TYO
Country
Japan
Employees (consolidated)
23
Related companies
15
§01

Basic information

BASIC
Head office
1-11-1 Nishigotanda, Shinagawa-ku, Tokyo
Chief executive
Shingo Nakamura
Capital
10,000,000
Employees (non-consolidated)
18 people
Employees (consolidated)
23 people
Start date
2016-11-17
End date
§02

Websites

1 DOMAINS
§03

Business

3
AI drug discovery platform aibVISDevelopment of low‑molecular‑weight drugs targeting mRNACreation of an in‑house pipeline for nucleic‑acid drugs
§04

Related companies

15 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
Nissan Chemical Corporation
Group Customer Alliance
Rakuria Pharmaceutical Co., Ltd.
Group Customer Alliance
Toray Industries, Inc.
Group Customer Alliance
KYOKUTO KOWA CORPORATION
Group Customer Alliance
Hokkaido System Science Co., Ltd.
Group Customer Alliance
Shionogi & Co., Ltd.
Group Customer Alliance
Dexcelars Co., Ltd.
Group Customer Alliance
Teijin Pharma Limited
Group Customer Alliance
Asahi Kasei Pharma Corporation
Group Customer Alliance
Takeda Pharmaceutical Company, Limited
Group Customer Alliance
かわさき新産業創造センター(KBIC)
Group
Oncodesign Services
Alliance
三菱ガス化学
Alliance
Emina Corporation
Alliance
東京慈恵会医科大学
Alliance
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

26 EVENTS

Veritas In Silico establishmentSources

Veritas In Silico was founded. Based on in‑silico RNA structural analysis technology, the company aimed to develop low‑molecular‑weight drugs and nucleic‑acid drugs targeting mRNA, and was established in Shibuya-ku, Tokyo.Sources

Veritas In Silico was founded. Based on in‑silico RNA structural analysis technology, the company aimed to develop low‑molecular‑weight drugs and nucleic‑acid drugs targeting mRNA, and was established in Shibuya-ku, Tokyo.Sources

Focused on nucleic‑acid drug development.Sources

Received Series A funding from Mitsubishi Gas Chemical Corporation (MGC) and three venture capital firms, marking the official launch.Sources

Conducted Series A fundraising. Received Series A funding from Mitsubishi Gas Chemical Corporation (MGC) and three venture capital firms, marking the official launch.Sources

Established a research base at Niigata College of Pharmacy. Professor Masayuki Irimoto, who belongs to the university, set up the research base.Sources

Established a research base at Niigata College of Pharmacy. Set up a research base at Niigata College of Pharmacy (Niigata City, Niigata Prefecture), where Professor Masayuki Irimoto, a leading figure in the sgASO field, belongs.Sources

Relocated headquarters to an office in Shinagawa-ku, Tokyo.Sources

Relocated headquarters office. Moved headquarters to the current office in Shinagawa-ku, Tokyo.Sources

Commenced joint research on mRNA‑targeted low‑molecular‑weight drug development with domestic pharmaceutical companies.Sources

Start of joint research with a pharmaceutical company on mRNA-targeted small molecule drug discovery. The first joint research with a domestic pharmaceutical company in the mRNA-targeted small molecule drug discovery business has begun.Sources

Established a research base for the mRNA‑targeted low‑molecular‑weight drug development business at the Kawasaki New Industry Creation Center (KBIC) in Kawasaki City, Kanagawa Prefecture.Sources

Establishment of a research base in Shin-Kawasaki. A research base for the mRNA-targeted small molecule drug discovery business has been established at the Kawasaki New Industry Creation Center – KBIC (Kawasaki City, Kanagawa Prefecture).Sources

Focused on the low‑molecular‑weight drug development business by conducting Series B fundraising. In addition to existing shareholders, received investment from three venture capital firms, and decided to actively pursue the low‑molecular‑weight drug development business.Sources

Series B fundraising. In order to focus on the small molecule drug discovery business, a Series B round of fundraising was conducted to confirm the intentions of shareholders. In addition to existing shareholders, we received investment from three venture capital firms that support the small molecule drug discovery business, and decided to seriously pursue the small molecule drug discovery business.Sources

Obtained a patent in Japan for a business model of low‑molecular‑weight drug development targeting RNA.Sources

Patent acquisition related to the business model. A patent related to the business model of small molecule drug discovery targeting RNA has been obtained (Japan).Sources

Decided to expand the drug discovery platform business for low‑molecular‑weight drugs targeting mRNA through the development and introduction of new technologies.Sources

Series C fundraising. Decided on a strategy to expand the platform business for discovering small molecule drugs targeting mRNA through the development and introduction of new technologies.Sources

Signed a memorandum of understanding (MOU) for business cooperation with Oncodesign Services, a French contract research organization (CRO), to broadly meet the needs of pharmaceutical companies aiming to develop low‑molecular‑weight drugs targeting mRNA.Sources

Business cooperation with a CRO. To broadly meet the needs of pharmaceutical companies aiming to develop small molecule drugs targeting mRNA, a basic agreement (MOU) on business cooperation was signed with Oncodesign Services, a French contract research organization (CRO).Sources

Listed on the Tokyo Stock Exchange Growth Market.Sources

Conducting joint drug discovery research aimed at developing mRNA‑targeted low‑molecular‑weight drugs with Toray Industries, Shionogi & Co., Ltd., Rakuoia Drug Discovery, and Takeda Pharmaceutical Company, Ltd.Sources

Listing on the Tokyo Stock Exchange Growth Market. Listed on the Tokyo Stock Exchange Growth Market.Sources

Joint drug discovery research with four pharmaceutical companies underway. Joint drug discovery research aimed at creating mRNA-targeted small molecule drugs is underway with Toray Industries, Ltd., Ajinomoto Co., Inc., Rakua Pharma Co., Ltd., and Takeda Pharmaceutical Company, Ltd.Sources

§07

News

0 ARTICLES

There is no news.

§08

Public records

GOV
National Tax Agency basic information4011001113744
Source: National Tax Agency Corporate Number Publication Site, basic three itemsSources
Trade name
株式会社Veritas In Silico
Trade name (kana)
ウェリタスインシリコ
Name in English
Corporation type
301
Address
〒141-0031 東京都品川区西五反田1丁目11番1号
Postal code
1410031
Prefecture code
13
City code
109
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2016-11-24
Update date
2023-12-20
Change date
2017-10-31
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record
1
Excluded from search
0
Processing type
12
Correction type
1
Trade name image ID
Address image ID
Sequence number
1791934
METI gBizINFO4011001113744
Source: gBizINFO (Ministry of Economy, Trade and Industry)Sources
Corporate number
4011001113744
Trade name
株式会社Veritas In Silico
Trade name (kana)
ウェリタスインシリコ
Trade name (alphabet)
Registry closure date
Reason for registry closure
Registered address
東京都品川区西五反田1丁目11番1号
Postal code
1410031
Prefecture
東京都
Prefecture code
13
City or district
品川区
City code
109
Street address
西五反田1丁目11番1号
Organisation type
301
Processing type
12
Correction type
1
Status
Representative
代表取締役社長 中村 慎吾
Capital
10000000
Employees
19
Employees (male)
Employees (female)
Business summary
Website URL
Year founded
Business category
Date established
Unified government qualification - grade
Unified government qualification - business items
Update date
2023-12-20
Key information
4011001113744
§09

Sources & updates

SOURCES
↑